| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 25.472 | 17.034 | 20.302 | 26.294 |
| Total Income - EUR | - | - | - | - | - | - | 25.472 | 17.539 | 20.302 | 26.294 |
| Total Expenses - EUR | - | - | - | - | - | - | 6.643 | 14.373 | 29.070 | 24.893 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 18.829 | 3.166 | -8.768 | 1.401 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 18.088 | 2.732 | -8.969 | 651 |
| Employees | - | - | - | - | - | - | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Oxivie Dr. Virginia Anamaria Boboc S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 627 | 35.287 | 24.939 | 16.467 |
| Current Assets | - | - | - | - | - | - | 21.121 | 29.413 | 17.751 | 20.603 |
| Inventories | - | - | - | - | - | - | 462 | 464 | 1.923 | 1.588 |
| Receivables | - | - | - | - | - | - | 257 | 13.407 | 7.816 | 0 |
| Cash | - | - | - | - | - | - | 20.402 | 15.542 | 8.012 | 19.015 |
| Shareholders Funds | - | - | - | - | - | - | 18.128 | 20.916 | 6.437 | 6.002 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 3.619 | 43.784 | 36.252 | 31.069 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oxivie Dr. Virginia Anamaria Boboc S.r.l.